ImmuneSensor Therapeutics

Focus: ImmuneSensor Therapeutics is a Dallas-based biotech company founded in 2014 focused on developing novel medicines targeting the cGAS-STING pathway, a validated immunology target with broad therapeutic potential.

Oncology

Profile data last refreshed 22h ago · AI intelligence enriched 2w ago

Open Jobs

About ImmuneSensor Therapeutics

AI assessmentNot Hiring

No open roles listed right now. Follow ImmuneSensor Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

5 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

IMSA101

Solid Tumor, Adult

Phase 1

Clinical Trials (1)

NCT06026254A Rollover Study for Subjects Who Completed Participation in IMSA101-101 Trial

Phase 1

Help build intelligence for ImmuneSensor Therapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Focused therapeutic approach on cGAS-STING pathway represents a differentiated scientific strategy with potential across multiple disease areas
Founded in 2014 with decade-long commitment to target validation suggests a team with conviction and deep immunology expertise
Early-stage biotech offers potential upside exposure for employees aligned with long-term value creation if programs succeed

Watch Out For

Zero active clinical trials and no disclosed pipeline programs signal either stealth development or limited clinical advancement to date
Critical data gaps on funding, financing, employee count, and job openings suggest limited transparency and possible resource constraints
No products marketed, no revenue, and no disclosed recent milestones create high execution risk with uncertain runway

Generated by Claude from ImmuneSensor Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

IMSB301

Type 1 Interferonopathies

Phase 1

Clinical Trials (1)

NCT07364513Phase 1b Safety Study of IMSB301 in Type 1 Interferonopathies

Phase 1

IMSA101

Solid Tumor, Adult

Phase 1/2

Clinical Trials (1)

NCT04020185Safety and Efficacy Study of IMSA101 in Refractory Malignancies

Phase 1/2

IMSA101

Oligoprogressive

Phase 2

Clinical Trials (1)

NCT05846659Study of PULSAR-ICI +/- IMSA101 in Patients with Oligoprogressive Solid Tumor Malignancies

Phase 2

IMSA101

Oligometastatic Disease

Phase 2

Clinical Trials (1)

NCT05846646Study of PULSAR-ICI +/- IMSA101 in Patients With Oligometastatic NSCLC and RCC

Phase 2

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Founded: 2014

Portfolio: 5 clinical trials

Top TAs: Oncology

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Oncology

3 pipeline

Marketed

Pipeline